Michael Mauro Discusses Therapy-Free CML Remission

Article

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission. 

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission. 

Mauro says patients with CML are often concerned about how long they have to stay on medication.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
Venetoclax May Provide Cost Savings to Patients vs BTK Inhibitors for CLL/SLL

Venetoclax May Provide Cost Savings to Patients vs BTK Inhibitors for CLL/SLL

May 17th 2024
Article

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Venetoclax Produces Lasting Responses in Relapsed/Refractory CLL

Venetoclax Produces Lasting Responses in Relapsed/Refractory CLL

May 15th 2024
Article

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

May 7th 2024
Article

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma

Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma

May 6th 2024
Article

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.

© 2024 MJH Life Sciences

All rights reserved.